GSK has turned to Brooke Shields to get the message ... and we've been able to penetrate those populations to a very high degree. In our number one segment, we're around 66% penetration ...

This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...

(Reuters) - British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any ...

GSK (NYSE:GSK) stock was up 3% in afternoon trading ... FDA was notified that the drug led to the formation of unacceptably high levels of N-nitrosodimethylamine (NDMA), a potential carcinogen.

(RTTNews) - Drug maker GSK plc (GSK, GSK.L) confirmed Wednesday that it has reached two confidential settlements in cases filed in California State Court against heartburn drug Zantac (ranitidine ...

(RTTNews) - Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma have been accepted for regulatory review in ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

GSK is betting that Blenrep--a blood-cancer treatment that U.S. drug regulators asked it to pull from the market in 2022--could get a second chance, part of a push by the British pharma giant to ...

GSK (NYSE:GSK) on Thursday announced its decision to advance its messenger-RNA-based flu vaccine candidate developed with CureVac (NASDAQ:CVAC) into late-stage development following a positive ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...

GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...